Bayer’s CEO and two fellow executive board members purchased a collective 2.9 million euros (US$3.5 million) worth of the German drugmaker’s shares after the stock was battered by billions in writedowns, litigation woes and a bleaker profit outlook.
Bayer executives buy 2.9 million euro in battered stock after writedowns
